KR20180031247A - Health supplementary food containing lactic acid bacteria - Google Patents

Abstract

The present invention relates to a health supplementary food containing lactic acid bacteria. More specifically, the health supplementary food comprises: mixed lactic acid bacteria; Bacillus subtillis; fructooligosaccharide; galactooligosaccharide; colostrum; glutamine; vitamin A; vitamin D; and zinc. The mixed lactic acid bacteria are Lactobacillus plantarum, Lactobacillus acidophilus, Lactobacillus rhamnosus, Lactobacillus casei, Lactobacillus paracasei, Lactobacillus reuteri, Lactobacillus salivarius, Bifidobacterium longum, Bifidobacterium breve, Bifidobacterium lactis, and Bifidobacterium bifidum. According to the present invention, the health supplementary food improves intestinal environment, induces regular bowel movements, and relieves constipation.

Description

{Health supplementary food containing lactic acid bacteria}

The present invention relates to a health supplement containing lactic acid bacteria. More particularly, the present invention relates to a health supplement containing lactic acid bacteria. More specifically, the present invention relates to a health supplement containing lactic acid bacteria, To a health supplement containing lactic acid bacteria which improves intestinal environment.

Intestinal bacteria present in our intestines can be divided into useful bacteria and harmful bacteria, and about 2000 kinds of them are bacteria. They continue to multiply, but because they constantly check for the growth of different bacteria, they usually live in the intestines at a constant rate, unless there is a rapid change in the intestinal environment. The harmful bacteria and the beneficial bacteria are in a competitive relationship. Thus, depending on which one is superior, it is determined whether the intestines are healthy or frequently occur. If the balance of intestinal bacteria is destroyed and the number of harmful bacteria is increased or too much of the beneficial bacteria is decreased, the function of the intestines will be lowered and various symptoms such as chronic diarrhea, abdominal pain, bloating, smell, nutritional deficiency, sepsis and shock will appear. The harmful bacteria mainly decompose the protein and produce odorous or toxic substances such as ammonia, hydrogen sulfide, amine, phenol, and indole that are harmful to human body. These harmful substances can penetrate into the blood through the intestinal mucosa and spread to the whole body, which can cause serious problems in the immune system. It can also cause intestinal inflammatory disease or diarrhea.

Lactic acid bacteria, known as beneficial bacteria in the intestines, inhibits the growth of harmful bacteria and coliform bacteria in the intestines and prevents the production of intestinal decay products such as ammonia, indole, and hydrogen sulfide, which cause various enteric diseases, and produces intestinal bacteria . In addition, it stimulates the immune system (macrophage, lymphocyte) of the living body and promotes the production of antibody in the blood, thereby improving the immune system. In addition, it inhibits the growth of the intestinal active oxygen and carcinogenic substances, Vitamin K and water soluble vitamin B group (B1, B2, B6, B12) are synthesized to improve the nutritional status of the intestines. Especially Lactobacillus sp. Cultures belonging to Lactobacillus sp. Have antibacterial activity when they are administered to humans or laboratory animals. They are also effective in improving stress constipation and diarrhea, inhibiting cholesterol synthesis, improving allergy and skin beauty. Especially, it has been reported that there are many effects that suppress Helicobacter pylori. Currently, lactic acid bacteria that inhibit Helicobacter pylori are also developed or sold as fermented milk and various health functional foods in Korea.

However, since the effect of the lactic acid bacteria alone on ingestion thereof is not great, the present invention intends to improve the intestinal environment by using mixed lactic acid bacteria and other ingredients.

KR 10-0720025 B1 KR 10-0885508 B1

Accordingly, an object of the present invention is to provide a health supplement containing lactic acid bacteria containing 11 kinds of mixed lactic acid bacteria, Bacillus subtilis, fructooligosaccharide, galactooligosaccharide, colostrum, glutamine, vitamin A, vitamin D and zinc, To improve the environment.

In order to achieve the above object, the present invention provides a health supplement containing lactic acid bacteria, which comprises a mixed lactic acid bacterium, Bacillus subtillis, fructooligosaccharide, galactooligosaccharide, colostrum, glutamine, vitamin A, vitamin D and zinc Wherein the mixed lactic acid bacteria are selected from the group consisting of Lactobacillus plantarum, Lactobacillus acidophilus, Lactobacillus rhamnosus, Lactobacillus casei, Lactobacillus paracase, But not limited to, Lactobacillus paracasei, Lactobacillus reuteri, Lactobacillus salivarius, Bifidobacterium longum, Bifidobacterium breve, Bifidobacterium lactis Bifidobacterium lactis) and Bifidobacterium bifidum.

10 to 15% by weight of fructooligosaccharide, 10 to 15% by weight of galactooligosaccharide, 20 to 30% by weight of colostrum, 0.01 to 0.05% by weight of vitamin A, 10 to 20% by weight of said mixed lactic acid bacteria, 0.1 to 1% by weight of bacillus subtilis, %, Vitamin D 0.0001 ~ 0.01 wt%, zinc 0.1 ~ 0.5 wt%, and the remainder of glutamine.

Lactobacillus plantarum, Lactobacillus acidophilus, Lactobacillus rhamnosus, Lactobacillus casei, Lactobacillus paracasei, and Lactobacillus spp. Lactobacillus reuteri, Lactobacillus salivarius, Bifidobacterium longum, Bifidobacterium breve, Bifidobacterium lactis, and Bifidobacterium lactis, The number of bacteria of Bifidobacterium bifidum is 1.0 × 10 ¹¹ cfu / g to 5.0 × 10 ¹¹ cfu / g, respectively.

0.5 to 3% by weight of amylase, 0.5 to 3% by weight of lipase, 0.5 to 3% by weight of protease and 0.5 to 3% by weight of lactose.

INDUSTRIAL APPLICABILITY According to the present invention, there is an effect of improving the intestinal environment, inducing a pleasant state, and helping to relieve constipation.

1 is a graph showing the results of Experimental Example 1 according to the present invention.

Hereinafter, the present invention will be described in detail.

The present invention relates to a pharmaceutical composition comprising lactic acid bacteria, Bacillus subtilis, fructooligosaccharide, galactooligosaccharide, colostrum, glutamine, vitamin A, vitamin D and zinc, wherein the mixed lactic acid bacteria are Lactobacillus plantarum ), Lactobacillus acidophilus, Lactobacillus rhamnosus, Lactobacillus casei, Lactobacillus paracasei, Lactobacillus reuteri, Lactobacillus reuteri, Lactobacillus spp. Bifidobacterium longis, Bifidobacterium breve, Bifidobacterium lactis, and Bifidobacterium bifidum may be used in the present invention. Examples of the Bifidobacterium bifidum include Bacillus subtilis, Bacillus subtilis, Lactobacillus salivarius, Bifidobacterium longum, Bifidobacterium breve, Bifidobacterium lactis, It is possible to improve the intestinal environment to induce a pleasant state and to have an effect of improving constipation .

In the present invention, improvement of the intestinal environment means increasing the total number of intestinal lactic acid bacteria and inhibiting the activity of intestinal harmful enzymes.

First, the lactic acid bacteria are sufficiently known as beneficial bacteria in the intestines, but the effect is insignificant when the lactic acid bacteria are used alone. Accordingly, the present invention uses various kinds of mixed lactic acid bacteria that help improve the intestinal environment, so as to have various physiological activities. Herein, each of the lactic acid bacteria may be in the form of a powder obtained by lyophilizing the culture solution after culturing, or may be in the form of coating or microcapsulating the powder, but the present invention is not limited thereto. It is also possible to purchase commercially available lactic acid bacteria in powder form. Here, the lyophilization, coating, and microcapsule treatment are well known in the art, and a description thereof will be omitted.

Hereinafter, the mixed lactic acid bacteria will be briefly described.

First, the Lactobacillus plantarum has a function to promote the growth of lactic acid bacteria, inhibition of harmful bacteria, and defecation activity.

The Lactobacillus acidophilus is highly viable in very high acidic environments such as the abdomen, bile and several small intestines, and acts to inhibit the growth of harmful bacteria while living in the intestines for a long time.

The Lactobacillus rhamnosus is excellent in survival ability even in a strong acidic environment, and is active in the digestion period for a long time and inhibits the growth of harmful bacteria.

The Lactobacillus casei is resistant to acid or heat and helps to grow Lactobacillus ashidophilus. In addition, it does not die by the digestive juice in the body, it goes to the small intestine, normalizes the intestinal flora, reduces intolerance of lactose, and helps digestion.

The above-mentioned Lactobacillus paracasei is excellent in viability even in strong acidity, and acts to inhibit the action of harmful bacteria in the stomach.

The Lactobacillus reuteri is strongly adsorbed on the barrier and continuously grows to secrete an antimicrobial substance to neutralize harmful bacteria, thereby increasing the total number of lactic acid bacteria in the intestines.

The Lactobacillus salivarius has antibacterial activity against pathogenic bacteria such as Escherichia coli, Staphylococcus aureus and Salmonella.

The Bifidobacterium longum has high resistance to gastric acid, pepsin and bile acid, and is excellent in long-term adhesion.

The Bifidobacterium breve is effective in suppressing E. coli, bacterial diarrhea, and alleviating adult allergies and atopic dermatitis.

Bifidobacterium lactis (Bifidobacterium lactis) is a lactic acid bacterium that enhances immunity and improves digestive power. It absorbs unnecessary substances in the intestines and colon, while it absorbs vitamins and minerals.

The Bifidobacterium bifidum maintains microflora in the intestines, promotes digestion, and reduces the production of E. coli infection and inflammation.

That is, the above-mentioned 11 types of mixed lactic acid bacteria survive in a strong acidic environment and inhibit the habitat of harmful bacteria by living in various gastrointestinal organs such as stomach and intestines, and help the form of beneficial bacteria and improve intestinal environment.

In addition to the mixed lactic acid bacteria, the present invention includes not only Bacillus subtilis, fructooligosaccharide, galactooligosaccharide, colostrum, glutamine, vitamin A, vitamin D and zinc, Induce, and remove succumbing.

First, the Bacillus subtilis is a bacterium that does not kill to the large intestine due to its strong vitality. It also plays a role in helping the pleasure of the intestines in the large intestine and improves intestinal environment together with mixed lactic acid bacteria. The Bacillus subtilis may also be in the form of a powder obtained by culturing Bacillus subtilis and lyophilizing the culture.

Since the fructooligosaccharide and the galactooligosaccharide are mostly fermented by intestinal bacteria, the fermented ingredient acidifies the intestinal environment and becomes a food which can be used by intestinal bacteria, It plays a role in propagating the bacterium Bifidus. Therefore, when taken together with the mixed lactic acid bacteria, it becomes a food of the lactic acid bacteria and significantly increases the total number of beneficial bacteria. However, since the fructooligosaccharide has poor stability in an acidic condition, stable galacto-oligosaccharides and fructooligosaccharides, which are easily fermented by bacteria, are used together in an acidic condition, So that they can operate stably.

In addition, the colostrum is a component that helps immunity due to a large amount of proteins and minerals. The glutamine is a kind of amino acid that constitutes a protein. It blocks the weakening of the immune system and removes protein waste. The absorption rate is further increased.

In addition, the vitamin A, vitamin D and zinc are essential nutrients for maintaining human health. They are taken together with lactic acid bacteria to increase the absorption rate thereof, and also help maintain the health of the consumers. The zinc is used as zinc oxide or zinc gluconate Lt; / RTI >

In the present invention, it is preferable that 10 to 20% by weight of the mixed lactic acid bacteria, 0.1 to 1% by weight of bacillus subtilis, 10 to 15% by weight of fructooligosaccharide, 10 to 15% by weight of galactooligosaccharide, 20 to 30% To 0.05% by weight of vitamin D, 0.0001% to 0.01% by weight of vitamin D, 0.1% to 0.5% by weight of zinc and the remaining amount of glutamine.

The mixed lactic acid bacteria may be selected from the group consisting of Lactobacillus plantarum, Lactobacillus acidophilus, Lactobacillus rhamnosus, Lactobacillus casei, Lactobacillus paracasei, Lactobacillus paracasei, Lactobacillus reuteri, Lactobacillus salivarius, Bifidobacterium longum, Bifidobacterium breve, Bifidobacterium lactis, Bifidobacterium lactis and Bifidobacterium bifidum are preferably in the range of 1.0 × 10 ¹¹ cfu / g to 5.0 × 10 ¹¹ cfu / g, respectively, If it is less than the above-mentioned range, the effect of improving intestinal environment is deteriorated.

The above-mentioned health supplement food is not limited to the formulations, and it may be formulated into various forms such as beverages, granules, preservatives, preservatives, coloring agents, , Tablets, capsules, and the like. Examples of the carrier, excipient and diluent include tosse, dextrose, sucrose, sorbitol, mannitol, xylitol, erythritol, maltitol, starch, acacia rubber, alginate, gelatin, calcium phosphate, calcium silicate, cellulose, methyl cellulose, Vaginal cellulose, polyvinylpyrrolidone, water, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate and mineral oil.

In addition, the amount of the health supplement food according to the present invention is not limited and may vary depending on the weight, age and sex of the recipient, but may be about 5 to 20 g / day, and may be appropriately selected by those skilled in the art.

Meanwhile, the health supplement food according to the present invention may further comprise 0.5-3% by weight of amylase, 0.5-3% by weight of lipase, 0.5-3% by weight of protease and 0.5-3% by weight of lactose, The inclusion of more nutrients helps to absorb the body's metabolic rate normally. Therefore, the inclusion of these digestive enzymes together with lactic acid bacteria accelerates the degradation rate of the food, and the intestinal environment can be improved more rapidly.

Hereinafter, the present invention will be described in detail with reference to specific examples.

(Example 1)

Lactobacillus plantarum MG208, Lactobacillus acidophilus MG501, Lactobacillus rhamnosus MG315, Lactobacillus casei MG311, and Lactobacillus paracasei. paracasei MG310, Lactobacillus reuteri MG505, Lactobacillus salivarius MG595, Bifidobacterium longum MG723, Bifidobacterium breve MG729, Bifidobacterium, Lactic acid bacteria of Bifidobacterium lactis MG740 and Bifidobacterium bifidum MG720 were respectively cultured and dextrin as an excipient was added in an amount of 1 times the weight of the culture medium and dispersed in a mixer, And dried to prepare powder. The number of bacteria in each powder ranged from 1.0 × 10 ¹¹ cfu / g to 5.0 × 10 ¹¹ cfu / g. The 11 types of lactic acid bacteria powder were mixed in the same amount.

In addition, Bacillus subtillis was cultured, dextrin as an excipient was added in an amount of 1 times the weight of the culture medium, and the mixture was dispersed with a mixer, and the mixture was freeze-spray-dried to prepare a powder. The number of bacteria in the powder was in the range of 1.0 × 10 ¹¹ cfu / g to 5.0 × 10 ¹¹ cfu / g.

Next, 17.5% by weight of the prepared mixed lactic acid bacteria powder, 1% by weight of Bacillus subtilis powder, 13% by weight of fructooligosaccharide, 13% by weight of galactooligosaccharide, 25% by weight of colostrum, 0.02% by weight of vitamin A, , 0.3% by weight of zinc gluconate, and the remaining glutamine.

(Test Example 1)

150 mg / kg of the composition prepared as in Example 1 was administered orally to 10 mice of 4 week old ICR mice once a day in purified water. The experimental animals were kept at 20 ± 2 ℃, 40 ~ 60% humidity and 12 hours of light cycle.

In the control group, 10 ICR mice at 4 weeks of age were bred under the same conditions as the experimental group, but the composition of Example 1 was not provided.

(Test Example 1-1)

Measurement of lactic acid bacteria in feces.

After collecting the fecal samples of the mice, 0.1 g of the fecal sample was suspended in 0.9 ml of a 0.1 M phosphate buffer (pH 6.8 containing 0.5% cysteine) with a micro sonicator and 0.2 ml of the suspension After serial dilution of 10-1 to 10-7 in a volume of 1: 10, 0.1 ml was spread on an MRS agar plate.

The plate was incubated for 48 hours in an anaerobic state (Bactron Anaerobic Chamber, Sheldon MFG. Inc., USA), and the number of colonies was then considered as the number of fecal LAB.

The results are shown in Fig.

As can be seen from Fig. 1 attached, it was confirmed that the levels of lactic acid bacteria in the feces of the mice were increased. This means that the total number of lactic acid bacteria in the intestines was increased.

(Test Example 1-2)

Measurement of inhibitory effect of intestinal harmful enzyme

Fecal samples of the mice were collected and the activity of the harmful enzymes resulting from intestinal bacteria remaining in the feces was measured. The feces were suspended in the same manner as in Test Example 1-1.

β- Glucosidase  Active measurement

1 ml of a reaction solution consisting of 0.8 ml of 2 mM p-nitrophenyl-β-D-glucopyranoside and 0.2 ml of the suspended fecal sample was reacted at 37 ° C. for 30 minutes and then 1 ml of 0.5 N NaOH was added to terminate the reaction. After the reaction solution was centrifuged at 3,000 rpm for 10 minutes, the supernatant was measured for its absorbance at 405 nm.

β- Gluconidase  Active measurement

1 ml of a reaction mixture consisting of 0.8 ml of 2 mM p-nitrophenyl-β-D-glucuronide and 0.2 ml of the suspended fecal sample was reacted at 37 ° C. for 30 minutes and then 1 ml of 0.5 N NaOH was added to terminate the reaction. After completion of the reaction, the reaction solution was centrifuged at 3,000 rpm for 10 minutes, and then the absorbance of the supernatant was measured at 405 nm.

Tryptophanase  Active measurement

0.2 ml of complete reagent solution (pH 7.5, containing 2.75 mg of pyridoxal phosphate, 19.6 mg of disodium EDTA dihydrate, and 10 mg of bovine serum albumin in 100 ml of 0.05 M potassium phosphate buffer), 0.2 ml of 20 mM tryptophan and 0.1 ml of suspended fecal sample The resulting reaction solution was incubated at 37 ° C for 1 hour, and 2ml of color reagent was added to terminate the reaction. The reaction solution in which the reaction was stopped was centrifuged at 3,000 rpm for 10 minutes, and the supernatant was measured for absorbance at 550 nm.

The results are shown in Table 1 below.

Test Example 1-2 Results. activity
(%) ? -glucosidase β-gluconidase Tryptophanase Before the test after 2 weeks Before the test after 2 weeks Before the test after 2 weeks Test group 100 77 100 88 100 81

As can be seen from the above Table 1, it was confirmed that the activities of β-glucosidase, β-glucosidase, and tryptophanase, which are intestinal toxic enzymes, after ingestion of the composition of Example 1 were significantly reduced.

(Test Example 2)

40 volunteers were recruited and volunteers were given 7 g of the composition of Example 1 once a day for 2 weeks. After 2 weeks, the condition of their defecation was checked and the defecation state of 6 I checked one of the stages ('like water', 'thinner', 'soft', 'normal', 'little crackle', 'stoned').

As a comparative example, 40 volunteers were recruited and lactose was administered once a day, 7 g each for 2 weeks. After 2 weeks, the state of their defecation was checked. , And to check one of the six steps ('water like', 'thinning', 'soft', 'normal', 'little crackle', 'stone like').

The results are shown in Table 2 below.

Test Example 1-2 Results. division Test Example Comparative Example I (person) Two weeks later (persons) I (person) Two weeks later (persons) It is like water. 0 0 0 0 Thin 0 0 0 0 soft One 15 3 3 is average 5 14 11 14 A bit hard 28 11 21 19 Stony 6 0 5 4

As can be seen from the above Table 2, it was confirmed that the test case improved the condition of the side to improve the constipation, but it was confirmed that there was almost no change in the side condition in the case of the lactose alone.

While the present invention has been particularly shown and described with reference to exemplary embodiments thereof, it is to be understood that the scope of the present invention is not limited to the disclosed exemplary embodiments. It will also be appreciated that many modifications and variations will be apparent to those skilled in the art without departing from the scope of the invention.

Claims (4)

Lactic acid bacteria, Bacillus subtillis, fructooligosaccharides, galactooligosaccharides, colostrum, glutamine, vitamin A, vitamin D and zinc,
The mixed lactic acid bacteria may be selected from the group consisting of Lactobacillus plantarum, Lactobacillus acidophilus, Lactobacillus rhamnosus, Lactobacillus casei, Lactobacillus paracase, paracasei, Lactobacillus reuteri, Lactobacillus salivarius, Bifidobacterium longum, Bifidobacterium breve, Bifidobacterium lactis (Bifidobacterium lactis), Bifidobacterium lactis ) And Bifidobacterium bifidum. ≪ RTI ID = 0.0 > 18. < / RTI >
The method according to claim 1,
10 to 15% by weight of fructooligosaccharide, 10 to 15% by weight of galactooligosaccharide, 20 to 30% by weight of colostrum, 0.01 to 0.05% by weight of vitamin A, 10 to 20% by weight of lactic acid bacteria, 0.1 to 1% by weight of bacillus subtilis, %, Vitamin D 0.0001 ~ 0.01 wt%, zinc 0.1 ~ 0.5 wt%, and the balance of glutamine.
3. The method of claim 2,
Lactobacillus plantarum, Lactobacillus acidophilus, Lactobacillus rhamnosus, Lactobacillus casei, Lactobacillus paracasei, Lactobacillus spp., Lactobacillus spp., Lactobacillus spp., Lactobacillus spp. Lactobacillus reuteri, Lactobacillus salivarius, Bifidobacterium longum, Bifidobacterium breve, Bifidobacterium lactis, Bifidobacterium lactis, and Bifidobacterium lactis, Wherein the number of bacteria of Bifidobacterium bifidum is 1.0 x 10 ¹¹ cfu / g to 5.0 x 10 ¹¹ cfu / g, respectively.
The method of claim 3,
A health supplement containing lactic acid bacteria, characterized by further comprising 0.5 to 3% by weight of amylase, 0.5 to 3% by weight of lipase, 0.5 to 3% by weight of protease, and 0.5 to 3% by weight of lactose.

Images